Evidence map›Paper›PMID 25688559›Full record

ArticlePLoS pathogens2015

CD8 T cell response maturation defined by anentropic specificity and repertoire depth correlates with SIVΔnef-induced protection.

Sama Adnan, Arnaud D Colantonio, Yi Yu, Jacqueline Gillis, Fay E Wong, Ericka A Becker, Michael Piatak, R Keith Reeves, Jeffrey D Lifson, Shelby L O'Connor and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Journal of virology · 2018
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Sama AdnanNew England Primate Research Center, Harvard Medical School, Southborough Campus, Southborough, Massachusetts, United States of America.
Arnaud D ColantonioNew England Primate Research Center, Harvard Medical School, Southborough Campus, Southborough, Massachusetts, United States of America.
Yi YuNew England Primate Research Center, Harvard Medical School, Southborough Campus, Southborough, Massachusetts, United States of America.
Jacqueline GillisNew England Primate Research Center, Harvard Medical School, Southborough Campus, Southborough, Massachusetts, United States of America.
Fay E WongNew England Primate Research Center, Harvard Medical School, Southborough Campus, Southborough, Massachusetts, United States of America.
Ericka A BeckerWisconsin National Primate Research Center, University of Wisconsin, Madison, Wisconsin, United States of America.
Michael PiatakAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, United States of America.
R Keith ReevesNew England Primate Research Center, Harvard Medical School, Southborough Campus, Southborough, Massachusetts, United States of America; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.
Jeffrey D LifsonAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, United States of America.
Shelby L O'ConnorWisconsin National Primate Research Center, University of Wisconsin, Madison, Wisconsin, United States of America.
R Paul JohnsonNew England Primate Research Center, Harvard Medical School, Southborough Campus, Southborough, Massachusetts, United States of America; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America; Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
New England Biolabs (United States) · USLeidos (United States) · USUniversity of Wisconsin–Madison · USRagon Institute of MGH, MIT and Harvard · US

Funding

ZETA CHAIN OF T CELL RECEPTOR INTERACTS W/ NEF OF SIV &HIV2P51RR000168 · NCRR · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WESTMORELAND, SUSAN V. · 1985 to 2011
$139.3M
VirologyU19AI095985 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2011 to 2015
$35.9M
New England Primate Research Center Base GrantP51OD011103 · OD · HARVARD MEDICAL SCHOOL · PI FLIER, JEFFREY S · 2012 to 2013
$24.7M
Pathology and Veterinary Service CoreP01AI071306 · NIAID · HARVARD MEDICAL SCHOOL · PI JOHNSON, R. PAUL · 2007 to 2011
$18.3M
Evaluating immunity elicited by CD8 T Cell responses targeting invariant epitopesR01AI108415 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI SHELBY L OCONNOR · 2014 to 2026
$9.5M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
MOUSE MODELS OF CANCER, BONE DISEASE, AND LACTATIONK26RR000168 · NCRR · OHIO STATE UNIVERSITY · PI ROSOL, THOMAS J · 2000 to 2004
$547k
NCRR NIH HHS K26 RR000168NCRR NIH HHS P51 RR000168NCRR NIH HHS RR00168NIAID NIH HHS AI071306NIAID NIH HHS AI095985NIAID NIH HHS P01 AI071306NIAID NIH HHS R01 AI108415NIAID NIH HHS T32 AI007387NIAID NIH HHS T32 AI07387-24NIAID NIH HHS U19 AI095985NIH HHS P51 OD011103
6 · The paper itself

Abstract

The live attenuated simian immunodeficiency virus (LASIV) vaccine SIVΔnef is one of the most effective vaccines in inducing protection against wild-type lentiviral challenge, yet little is known about the mechanisms underlying its remarkable protective efficacy. Here, we exploit deep sequencing technology and comprehensive CD8 T cell epitope mapping to deconstruct the CD8 T cell response, to identify the regions of immune pressure and viral escape, and to delineate the effect of epitope escape on the evolution of the CD8 T cell response in SIVΔnef-vaccinated animals. We demonstrate that the initial CD8 T cell response in the acute phase of SIVΔnef infection is mounted predominantly against more variable epitopes, followed by widespread sequence evolution and viral escape. Furthermore, we show that epitope escape expands the CD8 T cell repertoire that targets highly conserved epitopes, defined as anentropic specificity, and generates de novo responses to the escaped epitope variants during the vaccination period. These results correlate SIVΔnef-induced protection with expanded anentropic specificity and increased response depth. Importantly, these findings render SIVΔnef, long the gold standard in HIV/SIV vaccine research, as a proof-of-concept vaccine that highlights the significance of the twin principles of anentropic specificity and repertoire depth in successful vaccine design.

Indexed as

AnimalsCD8-Positive T-LymphocytesEnzyme-Linked Immunosorbent AssayEpitope MappingEpitopes, T-LymphocyteFlow CytometryImmune EvasionMacaca mulattanef Gene Products, Human Immunodeficiency VirusReverse Transcriptase Polymerase Chain ReactionSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeVaccines, AttenuatedEpitopes, T-Lymphocytenef Gene Products, Human Immunodeficiency VirusSAIDS VaccinesVaccines, Attenuated

Identifiers

PMID25688559
PMCPMC4334552
OpenAlexW2170777857

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.